[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466736":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":25,"locations":34,"responsibleParty":53,"collaborators":56,"id":60,"slug":11,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pimavanserin","EXPERIMENTAL",null,[13],"Drug: Pimavanserin",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","PD related Psychosis",[9],[20,23],{"name":21,"affiliation":5,"role":22},"Ciaran Considine, PhD","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":5,"role":22},"Richard Darby, MD",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Levi Pettit, BA","CONTACT","6154210569","levi.f.pettit@vumc.org",{"name":32,"role":28,"phone":11,"phoneExt":11,"email":33},"Katie Hay, MS","kaitlyn.r.hay@vumc.org",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Nashville","Tennessee","37212","United States",{"type":42,"coordinates":43},"Point",[44,45],-86.78444,36.16589,{"lat":45,"lon":44},[48,50],{"name":27,"role":28,"phone":49,"phoneExt":11,"email":30},"615-421-0569",{"name":32,"role":28,"phone":51,"phoneExt":11,"email":52},"6158757403","katie.orourke@vumc.org",{"type":22,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Daniel Claassen","Assoc Professor",[57],{"name":58,"class":59},"ACADIA Pharmaceuticals Inc.","INDUSTRY","100466736",false,"NCT05357612","Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases","Inclusion Criteria:\n\n* Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants\n* Healthy arm - age and gender matched to patient arm\n* Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.\n* Study partner available for study visits\n\nExclusion Criteria:\n\n* Prior stroke or other uncontrolled serious neurological or medical illness\n* Contra-indication or inability to tolerate MRI scan\n* Use of serotonergic medications in the last 6 weeks\n* Incapable of providing independent consent.\n* Pregnant or breastfeeding women\n* psychosis due to a metabolic, toxic, or primary psychiatric disease\n* Deemed unable to complete neurocognitive testing\n* For PD Participants: current or prior use of pimavanserin\n* Use of antipsychotics in the last 2 weeks",true,"ALL","50 Years","85 Years",{"count":70,"type":71},75,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age\u002Fsex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\\[18F\\]MH.MZ in both populations.",[77,78,79],"Neurodegenerative Diseases","Parkinson Disease","Parkinson Disease Psychosis","2025-08-06",{"date":82,"type":83},"2025-08-12","ACTUAL",{"date":85,"type":83},"2023-01-23",{"date":87,"type":71},"2026-08",{"name":5,"class":6},1]